JP2022510962A5 - - Google Patents

Info

Publication number
JP2022510962A5
JP2022510962A5 JP2021531115A JP2021531115A JP2022510962A5 JP 2022510962 A5 JP2022510962 A5 JP 2022510962A5 JP 2021531115 A JP2021531115 A JP 2021531115A JP 2021531115 A JP2021531115 A JP 2021531115A JP 2022510962 A5 JP2022510962 A5 JP 2022510962A5
Authority
JP
Japan
Prior art keywords
cancer
crenolanib
pharmaceutical composition
composition according
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US16/713,935 external-priority patent/US11602533B2/en
Publication of JP2022510962A publication Critical patent/JP2022510962A/ja
Publication of JP2022510962A5 publication Critical patent/JP2022510962A5/ja
Pending legal-status Critical Current

Links

JP2021531115A 2018-12-13 2019-12-13 クレノラニブ併用療法 Pending JP2022510962A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862779128P 2018-12-13 2018-12-13
US62/779,128 2018-12-13
US201962861424P 2019-06-14 2019-06-14
US62/861,424 2019-06-14
US16/713,935 2019-12-13
US16/713,935 US11602533B2 (en) 2018-12-13 2019-12-13 Crenolanib combination therapy
PCT/US2019/066308 WO2020123991A1 (en) 2018-12-13 2019-12-13 Crenolanib combination therapy

Publications (2)

Publication Number Publication Date
JP2022510962A JP2022510962A (ja) 2022-01-28
JP2022510962A5 true JP2022510962A5 (cg-RX-API-DMAC7.html) 2022-12-20

Family

ID=69596002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531115A Pending JP2022510962A (ja) 2018-12-13 2019-12-13 クレノラニブ併用療法

Country Status (5)

Country Link
US (2) US11602533B2 (cg-RX-API-DMAC7.html)
EP (1) EP3893874A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022510962A (cg-RX-API-DMAC7.html)
CN (1) CN110840893A (cg-RX-API-DMAC7.html)
WO (1) WO2020123991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
CN113491693B (zh) * 2020-03-19 2023-11-14 江苏恒瑞医药股份有限公司 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
CN118576599A (zh) * 2020-10-23 2024-09-03 和记黄埔医药(上海)有限公司 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
DK1641780T3 (da) 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
US20130230511A1 (en) 2012-02-03 2013-09-05 Board Of Regents, The University Of Texas System Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
CN105007939B (zh) * 2012-10-05 2018-10-19 卡德门企业有限公司 人抗vegfr-2/kdr抗体
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9617521B2 (en) * 2013-10-21 2017-04-11 Hemoshear, Llc In vitro model for a tumor microenvironment
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途

Similar Documents

Publication Publication Date Title
CN108601831B (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
Ellis et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non–small cell lung cancer patients
US20230181565A1 (en) Crenolanib combination therapy
JP2011511071A (ja) 肺癌を治療するためのピコプラチンおよびアムルビシン
CN104436194B (zh) 具有协同增效作用的抗癌组合物
CN114173785B (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
WO2010086964A1 (ja) がん治療のための併用療法
JP2008514577A5 (cg-RX-API-DMAC7.html)
JP2019536783A5 (cg-RX-API-DMAC7.html)
CN112236147A (zh) 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法
JP2019038797A5 (cg-RX-API-DMAC7.html)
Kamura et al. Chemotherapy for advanced or recurrent cervical cancer
JP2023517671A5 (cg-RX-API-DMAC7.html)
KR20230036274A (ko) 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
Horn et al. Emerging data with antiangiogenic therapies in early and advanced non–small-cell lung cancer
TW201628608A (zh) 治療或緩解高齡或末期癌症患者用之醫藥組合物
JP2016539149A5 (cg-RX-API-DMAC7.html)
Mizushima et al. A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer
CN116672345A (zh) Parp抑制剂和细胞毒性剂的联合产品及其用途
KR102265488B1 (ko) 암 화학 요법시의 부작용 경감제
CN119278047A (zh) 用于预防或治疗癌症的adp-核糖结合肽及adp-核糖的联合疗法
HK40017631A (en) Pharmaceutical compositions containing crenolanib and use thereof
Gore et al. Chemotherapy and Colorectal Cancer
CA3255803A1 (en) Combination therapy with adp-ribose binding peptide and adp-ribose for prevention or treatment of cancer